With its Q3 2025 results on Tuesday, Aurinia Pharmaceuticals (AUPH) said that it recently responded to an information request ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Executive accused of making false statements about a drug and soliciting a bribe. Baidu’s Apollo Go hits driverless ride ...

Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.

On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents. The biotechnology company posted revenue of $73.5 million in the period, beating Street forecasts. Three ...